112 related articles for article (PubMed ID: 10706935)
21. Generation and in vitro characterisation of inhibitory nanobodies towards plasminogen activator inhibitor 1.
Zhou X; Hendrickx ML; Hassanzadeh-Ghassabeh G; Muyldermans S; Declerck PJ
Thromb Haemost; 2016 Nov; 116(6):1032-1040. PubMed ID: 27604413
[TBL] [Abstract][Full Text] [Related]
22. Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties.
Ngo TH; Hoylaerts MF; Knockaert I; Brouwers E; Declerck PJ
J Biol Chem; 2001 Jul; 276(28):26243-8. PubMed ID: 11342530
[TBL] [Abstract][Full Text] [Related]
23. A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
Mathiasen L; Dupont DM; Christensen A; Blouse GE; Jensen JK; Gils A; Declerck PJ; Wind T; Andreasen PA
Mol Pharmacol; 2008 Sep; 74(3):641-53. PubMed ID: 18559377
[TBL] [Abstract][Full Text] [Related]
24. Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors.
Nakashima A; Kobayashi T; Terao T
Gynecol Obstet Invest; 1996; 42(2):95-101. PubMed ID: 8878712
[TBL] [Abstract][Full Text] [Related]
25. Mapping of the epitope of a monoclonal antibody protecting plasminogen activator inhibitor-1 against inactivating agents.
Bødker JS; Wind T; Jensen JK; Hansen M; Pedersen KE; Andreasen PA
Eur J Biochem; 2003 Apr; 270(8):1672-9. PubMed ID: 12694180
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
27. Protein movement during complex-formation between tissue plasminogen activator and plasminogen activator inhibitor-1.
Björquist P; Ehnebom J; Deinum J
Biochim Biophys Acta; 1999 Apr; 1431(1):24-9. PubMed ID: 10209275
[TBL] [Abstract][Full Text] [Related]
28. Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1.
Mimuro J; Kaneko M; Murakami T; Matsuda M; Sakata Y
Biochim Biophys Acta; 1992 Dec; 1160(3):325-34. PubMed ID: 1477106
[TBL] [Abstract][Full Text] [Related]
29. Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding.
Verhamme I; Kvassman JO; Day D; Debrock S; Vleugels N; Declerck PJ; Shore JD
J Biol Chem; 1999 Jun; 274(25):17511-7. PubMed ID: 10364183
[TBL] [Abstract][Full Text] [Related]
30. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1.
Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA
Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886
[TBL] [Abstract][Full Text] [Related]
31. Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin function.
Gorlatova NV; Elokdah H; Fan K; Crandall DL; Lawrence DA
J Biol Chem; 2003 May; 278(18):16329-35. PubMed ID: 12606560
[TBL] [Abstract][Full Text] [Related]
32. Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
Grimsley PG; Normyle JF; Brandt RA; Joulianos G; Chesterman CN; Hogg PJ; Owensby DA
Thromb Res; 1995 Aug; 79(4):353-61. PubMed ID: 7482438
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Robbie LA; Dummer S; Booth NA; Adey GD; Bennett B
Br J Haematol; 2000 May; 109(2):342-8. PubMed ID: 10848822
[TBL] [Abstract][Full Text] [Related]
34. A method for defining binding sites involved in protein-protein interactions: analysis of the binding of plasminogen activator inhibitor 1 to the somatomedin domain of vitronectin.
Royle G; Deng G; Seiffert D; Loskutoff DJ
Anal Biochem; 2001 Sep; 296(2):245-53. PubMed ID: 11554720
[TBL] [Abstract][Full Text] [Related]
35. Localization of a vitronectin binding region of plasminogen activator inhibitor-1.
Padmanabhan J; Sane DC
Thromb Haemost; 1995 May; 73(5):829-34. PubMed ID: 7482411
[TBL] [Abstract][Full Text] [Related]
36. Characterization of monoclonal antibodies against human tissue plasminogen activator (tPA): quantitation of free tPA in human cell cultures by an ELISA.
Kurokawa T; Toyoda Y; Iwasa S
J Biochem; 1991 Feb; 109(2):217-22. PubMed ID: 1713912
[TBL] [Abstract][Full Text] [Related]
37. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.
Sipley JD; Alexander DS; Testa JE; Quigley JP
Proc Natl Acad Sci U S A; 1997 Apr; 94(7):2933-8. PubMed ID: 9096324
[TBL] [Abstract][Full Text] [Related]
38. AS3288802, a highly selective antibody to active plasminogen activator inhibitor-1 (PAI-1), exhibits long efficacy duration in cynomolgus monkeys.
Kashiwagi R; Sato R; Masumoto M; Yoshino M; Tanaka H
Biologicals; 2020 Sep; 67():21-28. PubMed ID: 32828642
[TBL] [Abstract][Full Text] [Related]
39. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.
Declerck PJ; Verstreken M; Collen D
Thromb Haemost; 1995 Nov; 74(5):1305-9. PubMed ID: 8607114
[TBL] [Abstract][Full Text] [Related]
40. Epitope specificity of 30 monoclonal antibodies against cytokeratin antigens: the ISOBM TD5-1 Workshop.
Stigbrand T; Andrés C; Bellanger L; Bishr Omary M; Bodenmüller H; Bonfrer H; Brundell J; Einarsson R; Erlandsson A; Johansson A; Leca JF; Levi M; Meier T; Nap M; Nustad K; Seguin P; Sjödin A; Sundström B; van Dalen A; Wiebelhaus E; Wiklund B; Arlestig L; Hilgers J
Tumour Biol; 1998; 19(2):132-52. PubMed ID: 9486565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
